CPT code 87562 represents a nucleic acid probe assay used to detect and quantify infection with Mycobacterium avium intracellulare, a group of acid-fast mycobacteria. This molecular diagnostic code is important for confirming mycobacterial infection, guiding antimicrobial therapy, and informing public health surveillance. The test is typically performed in clinical or hospital laboratories with molecular diagnostic capability, and it supports management of patients with suspected mycobacterial disease.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for the assay, common billing and coding considerations, and national benchmarking and policy context where available. The publication summarizes reimbursement benchmarks, payer coverage patterns, documentation expectations, and operational notes relevant to laboratories and billing teams.

The piece provides clinicians, laboratory managers, and revenue cycle professionals with actionable reference material on coding practices, payer coverage landscape, and typical sites of service for molecular mycobacterial testing. Data not available in the input are noted where applicable.